Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing

J Clin Invest. 2000 Dec;106(11):1417-25. doi: 10.1172/JCI11182.

Abstract

Neuroendocrine ACTH secretion responds to peripheral inflammatory and stress signals. We previously demonstrated that the proinflammatory cytokine, leukemia inhibitory factor (LIF), affects the hypothalamo-pituitary-adrenal axis (HPA) by stimulating in vitro and in vivo pituitary proopiomelanocortin (POMC) gene expression and ACTH secretion and by potentiating the action of hypothalamic corticotropin releasing hormone (CRH). Whereas pathways shown thus far to regulate POMC expression exclusively involve cAMP or calcium, we here describe a direct and indirect STAT3-dependent regulation of POMC transcription by LIF. Using progressive 5'-deletions of POMC promoter, we identified a LIF-responsive -407/-301 region that contains two juxtaposed sequences within -399/-379 related to a STAT3 DNA-binding motif. Each sequence within -399/-379 separately corresponds to a low-affinity and direct binding site for STAT3, but, in combination, these sequences bind STAT3 cooperatively and with high affinity. Moreover, LIF-activated STAT3 indirectly mediates LIF corticotroph action by inducing and potentiating CRH-induced c-fos and JunB expression and binding to the POMC AP-1 element. We therefore conclude that both a direct and indirect route mediate LIF-induced STAT3 activation of POMC transcription. Demonstration of STAT3-dependent regulation of the POMC gene represents a powerful mechanism for immuno-neuroendocrine interfacing and implies a direct stimulation of ACTH secretion by inflammatory and stress-derived STAT3-inducing cytokines.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Base Sequence
  • Binding Sites
  • Corticotropin-Releasing Hormone / pharmacology
  • DNA / genetics
  • DNA / metabolism
  • DNA-Binding Proteins / metabolism
  • DNA-Binding Proteins / physiology*
  • Drug Synergism
  • Gene Expression Regulation / drug effects
  • Growth Inhibitors / metabolism
  • Growth Inhibitors / pharmacology
  • Immune System / physiology
  • Interleukin-6*
  • Leukemia Inhibitory Factor
  • Luciferases / genetics
  • Luciferases / metabolism
  • Lymphokines / metabolism
  • Lymphokines / pharmacology
  • Neurosecretory Systems / physiology
  • Nuclear Receptor Subfamily 4, Group A, Member 2
  • Pro-Opiomelanocortin / genetics*
  • Pro-Opiomelanocortin / metabolism
  • Promoter Regions, Genetic / genetics
  • Protein Binding
  • Proteins / genetics
  • Proteins / metabolism
  • Proto-Oncogene Proteins c-fos / genetics
  • Proto-Oncogene Proteins c-jun / genetics
  • Rats
  • Recombinant Fusion Proteins / drug effects
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / metabolism
  • Repressor Proteins*
  • Response Elements / genetics
  • STAT3 Transcription Factor
  • Sequence Deletion
  • Suppressor of Cytokine Signaling 3 Protein
  • Suppressor of Cytokine Signaling Proteins
  • Trans-Activators / metabolism
  • Trans-Activators / physiology*
  • Transcription Factors / genetics
  • Transcription, Genetic / drug effects
  • Tumor Cells, Cultured

Substances

  • DNA-Binding Proteins
  • Growth Inhibitors
  • Interleukin-6
  • Leukemia Inhibitory Factor
  • Lymphokines
  • Nr4a2 protein, rat
  • Nuclear Receptor Subfamily 4, Group A, Member 2
  • Proteins
  • Proto-Oncogene Proteins c-fos
  • Proto-Oncogene Proteins c-jun
  • Recombinant Fusion Proteins
  • Repressor Proteins
  • STAT3 Transcription Factor
  • Socs3 protein, rat
  • Stat3 protein, rat
  • Suppressor of Cytokine Signaling 3 Protein
  • Suppressor of Cytokine Signaling Proteins
  • Trans-Activators
  • Transcription Factors
  • Pro-Opiomelanocortin
  • DNA
  • Corticotropin-Releasing Hormone
  • Luciferases